-
How to open the ceiling of the pharmaceutical equipment industry?
Time of Update: 2022-04-15
In recent years, innovative drugs including antibody drugs, cell therapy, and gene drugs have flourished, bringing new development opportunities to the upstream equipment and consumables industries .
-
The Centralized Procurement Alliance of Chinese Patent Medicines in 6 Provinces is approaching, and a large number of medicines will be reduced in price
Time of Update: 2022-04-15
[Pharmaceutical Network Market Analysis] In recent years, many places have carried out centralized procurement pilots for some varieties of Chinese patent medicines with high demand and high price .
-
Pension concept stocks continue to be popular, and many stocks such as Yuexin Health have daily limit
Time of Update: 2022-04-15
Several pharmaceutical stocks involving the concept of elderly care have risen sharply today, including Yuexin Health, Dongcheng Pharmaceutical, Dean Diagnostics, Xiangyu Medical, Taiji Group, etc.
The two parties plan to jointly initiate the establishment of Nuokai Dongcheng Nuclear Pharmaceutical Industry Investment fund (limited partnership) with a fund size of 500 million yuan .
-
1 new pharmaceutical stock is subscribed today, focusing on the field of domestic small molecule innovative drugs
Time of Update: 2022-04-15
This product is the second-generation ALK kinase inhibitor independently developed by the company, which is used for the treatment of advanced ALK-positive non-small cell lung cancer.
-
Strong pharmaceutical demand drives the development of pharmaceutical machines, and many companies such as Canaan Technology have achieved gratifying performance
Time of Update: 2022-04-15
Regarding the changes in performance, Canaan Technology said that during the reporting period, the company continued to steadily improve the operational efficiency of various businesses, optimize the revenue structure, and coordinate the development of upstream and downstream businesses in the entire industry chain to ensure the company's oral solid preparation equipment, biological preparation fluid equipment and various businesses.
-
The new pharmaceutical shares listed on the Science and Technology Innovation Board have been losing money for four consecutive years!
Time of Update: 2022-04-15
For example, in the domestic NMIBC field, in addition to Asieris' APL-1202, there are 6 innovative drugs of other companies in clinical stage; In the field of HSIL treatment, there are also 3 domestic therapeutic drugs targeting HSIL or CIN2/3 that have entered clinical trials .
-
Under the new policy of medical reform, pharmaceutical distribution enterprises have accelerated their transformation!
Time of Update: 2022-04-15
The company has stated that under a clear development strategy, around the goal of improving value to increase market value, standardize operations, adhere to the concept of "performance is king" and further promote enterprise transformation and innovation, continue to optimize business models and profitability, and improve.
-
The "water seller" collapsed!
Time of Update: 2022-03-09
S. Department of Commerce had a set of routine verification procedures for the reasonable use of these products (that is, for personal use, not for resale), but in the past two years due to the impact of the new crown pneumonia epidemic, it could not be completed in time, which led WuXi Biologics to enter the UVL .
-
"Rising" has become a hot word of the year, and these traditional Chinese medicine companies have received attention
Time of Update: 2022-03-09
Comments: The raw materials of traditional Chinese medicine have been put on the cloak of capital, and the price changes have largely been separated from their real value .
-
14 domestic class 1 new drugs are coming!
Time of Update: 2022-03-09
Sales of some ALK inhibitors in Chinese public medical institutions and physical pharmacies in Chinese cities in 2020 (unit: 10,000 yuan) Source: Minet database Innovative Drug One Brother, the first new drug introduced by Hengrui Medicine, known as "Innovative Drug One Brother" Hengrui Medicine, known as Hengrui Medicine, currently has 10 innovative drugs (9 category 1 new drugs) approved for marketing in China, of which anti-tumor drugs account for "half of the country" .
-
Burnet prices rose slightly, and the weak inventory pushed the market to continue to rise!
Time of Update: 2022-03-09
Years ago, there were not many supplies in the market, and the price fluctuated slightly, but the overall attention was not high .
-
The latest results of a group of pharmaceutical companies listed on the Science and Technology Innovation Board are announced
Time of Update: 2022-03-09
Among them, BeiGene, with a market value of 100 billion, has become the first listed pharmaceutical company in 3 places, with a total R&D expenditure of more than 20 billion yuan in the past 4 years; 6 companies, including Nuohezhiyuan, Nanowei Technology, and Jiahe Meikang, are expected to increase their net profit in 2021.
-
Centralized hanging network, inter-provincial joint procurement, centralized procurement of traditional Chinese medicine formula granules is approaching!
Time of Update: 2022-03-09
According to the industry, since proprietary Chinese medicines have been included in volume procurement, the profit margins of the entire proprietary medicines have been greatly reduced, and most of the traditional Chinese medicines are covered by medical insurance reimbursement, resulting in a large number of medicines that were originally used for clinical promotion The representative turned to high-end Chinese herbal decoction pieces and formula granules .
-
Annual performance PK of multinational pharmaceutical companies!
Time of Update: 2022-03-09
Pfizer: New crown vaccine + oral drugs drive performance soaring Pfizer CEO Albert Bourla said that Pfizer’s sales in 2021 are expected to exceed $80 billion, the highest annual figure ever .
-
Fujian announces the third batch of medical insurance key monitoring drugs and the list of key drugs
Time of Update: 2022-03-09
24), with the approval of the Provincial Medical Insurance Bureau, the "Third Batch of Medical Insurance Key Monitoring Drugs List" and the "Third Batch of Medical Insurance Focused Drug List" to be announced .
-
Six key words in the new stage of centralized procurement!
Time of Update: 2022-03-09
At the beginning of the new year, centralized procurement with volume is still an important starting point for the new medical reform, especially the "three medical linkage" reform with medical insur
-
The three major varieties are out, and the top 10 best-selling drugs in 2022 will undergo great changes!
Time of Update: 2022-03-09
The biological targeting agent Dabitux may rank among the top 10 best-selling drugs in the world for the first time this year with a gratifying sales growth rate, while the anticoagulants Xarelto/Xarelto (rivaroxaban) and small molecules, which were at the bottom last year The BTK inhibitor Yike/Imbruvica (ibrutinib) and the ophthalmic biologic drug Aliya/Eylea (aflibercept), which are about to be impacted by biosimilars, were tragically eliminated .
-
Stock price dives, R&D burns money, biopharmaceutical companies move forward tenaciously in 2021
Time of Update: 2022-03-08
Strong research and development strength is more favored by capital Wind data shows that from 2018 to 2020, A-share biopharmaceutical companies invested an average of 296 million yuan in research and development each year, much higher than the 146 million yuan of the entire pharmaceutical industry .
-
A blockbuster medical law will go into effect, affecting doctors across the country
Time of Update: 2022-03-08
At the meeting, Xu Yucai, a well-known medical reform expert, explained the multi-point practice policy of doctors in the era of physician law for more than a thousand guests from all over the country .
-
Guangxi promotes "going out" of traditional Chinese medicine and builds a joint laboratory with ASEAN
Time of Update: 2022-03-08
Guangxi Zhuang Autonomous Region Traditional Chinese Medicine Administration introduced on the 7th that during the "14th Five-Year Plan" period, Guangxi will implement the open cooperation project of traditional Chinese medicine Zhuang Yao medicine, promote the construction of Guangxi-ASEAN traditional medicine research and development center, and cooperate with ASEAN countries to build a joint laboratory .